Skip to main content
Satish Shah, MD, Oncology, Gettysburg, PA

SatishAShahMD

Oncology Gettysburg, PA

President and CEO PA Cancer Specialist and Research institute

Dr. Shah is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Shah's full profile

Already have an account?

  • Office

    20 Expedition Trl
    Ste 101
    Gettysburg, PA 17325
    Phone+1 717-334-4033
    Fax+1 717-334-5599

Education & Training

  • Penn State Milton S Hershey Medical Center
    Penn State Milton S Hershey Medical CenterFellowship, Hematology and Medical Oncology, 1986 - 1988
  • UPMC Medical Education (Harrisburg)
    UPMC Medical Education (Harrisburg)Residency, Internal Medicine, 1983 - 1986
  • University of Texas Southwestern Medical Center
    University of Texas Southwestern Medical CenterFellowship, Hematology and Medical Oncology, 1983 - 1983
  • Baroda Medical College
    Baroda Medical CollegeClass of 1980

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 1987 - 2025
  • PA State Medical License
    PA State Medical License 1984 - 2024

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2012-2013

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Gettysburg Cancer Center Changes Name
    Gettysburg Cancer Center Changes NameSeptember 20th, 2022
  • OneOncology Platform Continues to Expand with Gettysburg Cancer Center
    OneOncology Platform Continues to Expand with Gettysburg Cancer CenterJune 23rd, 2021
  • Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors
    Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid TumorsMarch 24th, 2021

Research History

  • Director of Research23 clinical trials at present1990 - Present

Professional Memberships